XRAY stock forecast, quote, news & analysis

Key Takeaways

• Dentsply Sirona (XRAY) shares climbed roughly 23% over the past 30 days, rebounding from about $8.56 in early October to near $10.54.
• The recovery followed a series of commercial, reimbursement, and balance-sheet developments, including expanded North American distribution partnerships and debt covenant relief.
• The rally came after a steep multi-month decline; over the last quarter the stock is still down around 26% from its early-August levels.
• Demand softness in dental implants, orthodontics, and equipment, along with cautious guidance and tariff pressures, has weighed on the broader turnaround narrative.
• The company maintained its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
• Investors can review detailed Price Targets, Earnings, and Forecast data on additional pages to inform their research.
• Explore Trending AI Robots to see how automated strategies are positioning across the market.

Dentsply Sirona (XRAY) Company Overview and Market Position

Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies. Headquartered in Charlotte, North Carolina, the company was formed through the 2016 combination of Dentsply International and Sirona Dental Systems. Its portfolio spans dental consumables, laboratory products, implants, connected equipment, and digital dentistry solutions such as CAD/CAM systems and the SureSmile clear-aligner platform. Through its Wellspect HealthCare subsidiary, the company also supplies urology and continence-care medical devices.

The company sells into dental practices, laboratories, and institutions globally, and it has been expanding its North American dealer network to broaden access to its connected technology ecosystem. Investors follow XRAY as a bellwether for elective dental procedure demand and as a turnaround story centered on cost discipline, commercial execution, and digital dentistry adoption.

Dentsply Sirona (XRAY) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, XRAY has gained approximately 23%, rising from a closing level near $8.56 in early October to roughly $10.54. The move marked a sharp reversal after the stock bottomed in the low-$8 range in mid-to-late October.

The longer-term picture remains more challenging. Measured over the last quarter, the stock is still down roughly 26% from its early-August level near $14.27. That decline reflects a pullback that began in the summer, when second-quarter results renewed concerns about dental demand, and continued into October before the recent rebound took hold.

What Drove XRAY Stock Price in the Last 30 Days

Several verified developments coincided with the stock's recovery. In early October, Dentsply Sirona announced an expanded distribution agreement with Midwest Dental Equipment & Supply, extending the relationship beyond consumables to include the company's technology portfolio effective November 1, 2026. The move marked the company's seventh North American dealer partnership enhancement of the year, broadening access to its digital dentistry ecosystem.

Around the same time, the company's Wellspect HealthCare subsidiary announced that its Surity urinary-management portfolio could qualify for traditional U.S. Medicare reimbursement for eligible patients. Dentsply Sirona also disclosed that lenders had consented to amendments to its revolving credit facility and related note agreements, providing covenant relief and reducing near-term balance-sheet pressure. The subsequent confirmation of a third-quarter earnings call scheduled for November 5, 2026 helped sustain the momentum into early November.

What Drove XRAY Stock Performance Over the Last Quarter

The quarterly decline was driven primarily by fundamental concerns rather than a single event. Second-quarter results, reported in early August, beat earnings and revenue estimates but showed net sales down about 4% as weaker demand for implants, orthodontics, and dental equipment offset growth at Wellspect. Management maintained its full-year guidance, but cautious commentary and continued margin pressure weighed on sentiment.

Broader factors also played a role, including tariff-related cost exposure, softness in elective dental procedures, and investor caution around the pace of the company's turnaround and restructuring efforts. The recent distribution expansion and covenant relief have begun to reframe that narrative, though the stock remains well below its 52-week high.

Trending AI Robots

Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in the curated Trending AI Robots section. These automated systems differ in strategy, timeframe, and performance metrics, giving traders a way to observe how data-driven approaches are positioning across a range of markets and conditions. The section is designed to surface the bots gaining the most traction and relevance at any given time. For investors interested in how AI-driven analysis approaches stocks like XRAY, the Trending AI Robots page offers a practical starting point.

XRAY Stock Forecast Drivers: What Investors Should Watch Next

The most immediate catalyst is the company's third-quarter earnings report and conference call scheduled for November 5, 2026. Investors will be watching revenue trends across dental consumables, implants, and digital dentistry, as well as any updates to the 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.

Beyond earnings, key factors include the pace of the North American distribution reset, demand recovery in elective and preventive dental procedures, tariff and trade-policy developments, and continued progress on cost and restructuring initiatives. Analyst expectations and any revisions to price targets will also influence sentiment, as will the company's ability to sustain the recent balance-sheet and commercial momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations